| A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma (NCT07185477) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-15 |
| Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorder in Patients With Intestinal Acute Graft-Versus-Host Disease (aGVHD) (NCT07188909) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-15 |
| Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial (NCT07165769) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-04 |
| BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis (NCT07151690) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-04 |
| CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors (NCT07234110) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-03 |
| The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients (NCT06880380) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-01 |
| Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML (NCT07304232) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-01 |
| Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia (NCT07169565) | Institute of Hematology & Blood Diseases Hospital, China | 2025-09-01 |
| Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients (NCT07132684) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-31 |
| Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration (NCT07115667) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-25 |
| ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia (NCT07106684) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-10 |
| MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma (NCT07106736) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-10 |
| A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma (NCT07106671) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-10 |
| ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma (NCT07106710) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-10 |
| BCMA/CD3 BsAb Therapy for POEMS Syndrome (NCT07115654) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-10 |
| Effect of a Simplified Mindfulness Intervention on Health-related Quality of Life in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Prospective Single-Center Randomized Controlled Trial (NCT07127562) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-07 |
| Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) (NCT07063199) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-01 |
| Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy (NCT07127289) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-01 |
| Romiplostim N01 for Chemotherapy-induced Thrombocytopenia (NCT07063225) | Institute of Hematology & Blood Diseases Hospital, China | 2025-08-01 |
| Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients (NCT06918834) | Institute of Hematology & Blood Diseases Hospital, China | 2025-07-24 |
| The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT (NCT07126782) | Institute of Hematology & Blood Diseases Hospital, China | 2025-07-20 |
| Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia (NCT07078721) | Institute of Hematology & Blood Diseases Hospital, China | 2025-07-20 |
| A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NCT07068906) | Institute of Hematology & Blood Diseases Hospital, China | 2025-07-15 |
| Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study (NCT07169487) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-28 |
| SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies (NCT07153068) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-28 |
| uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies (NCT07109518) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-28 |
| CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies (NCT07106749) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-28 |
| A Study of CT0596 in Plasma Cell Leukemia (NCT06988059) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-25 |
| A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 (NCT07034508) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-20 |
| CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia (NCT06622694) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-19 |
| Optimal Timing of Hepatitis B Vaccination After Transplants (NCT06888479) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-01 |
| Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL (NCT07106723) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-01 |
| Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia (NCT06955858) | Institute of Hematology & Blood Diseases Hospital, China | 2025-05-30 |
| A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT06880354) | Institute of Hematology & Blood Diseases Hospital, China | 2025-05-22 |
| Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial (NCT06992128) | Institute of Hematology & Blood Diseases Hospital, China | 2025-05-22 |
| Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases (NCT07135778) | Institute of Hematology & Blood Diseases Hospital, China | 2025-05-19 |
| Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma (NCT06996132) | Institute of Hematology & Blood Diseases Hospital, China | 2025-05-09 |
| Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia (NCT07585734) | Institute of Hematology & Blood Diseases Hospital, China | 2025-04-30 |
| Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients (NCT06900088) | Institute of Hematology & Blood Diseases Hospital, China | 2025-04-25 |
| Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease (NCT06793475) | Institute of Hematology & Blood Diseases Hospital, China | 2025-04-09 |
| CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma (NCT07249073) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-28 |
| Newly-diagnosed Pediatric Ph-positive B-ALL Protocol (NCT07152041) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-28 |
| Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety (NCT07185503) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-25 |
| Cohort of Cord Blood Bank (NCT07249099) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-25 |
| BCMA CAR-T for Dynamic High-risk Multiple Myeloma (NCT06880393) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-18 |
| Newly-diagnosed Pediatric T-cell ALL Protocol (NCT06855810) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-11 |
| Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients (NCT07169500) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-03 |
| Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM (NCT07109323) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-03 |
| An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia (NCT06799611) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-03 |
| A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP (NCT06838949) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-03 |
| Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol (NCT06882057) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-03 |
| Reproductive and Mental Health of Patients With Aplastic Anemia (NCT06936930) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-03 |
| Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model (NCT06880419) | Institute of Hematology & Blood Diseases Hospital, China | 2025-03-03 |
| Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia (NCT06921980) | Institute of Hematology & Blood Diseases Hospital, China | 2025-02-25 |
| The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation (NCT06792682) | Institute of Hematology & Blood Diseases Hospital, China | 2025-02-14 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases (NCT06941129) | Institute of Hematology & Blood Diseases Hospital, China | 2025-02-11 |
| Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China (NCT06900114) | Institute of Hematology & Blood Diseases Hospital, China | 2025-02-08 |
| BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma (NCT06793449) | Institute of Hematology & Blood Diseases Hospital, China | 2025-02-05 |
| Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia (NCT07010237) | Institute of Hematology & Blood Diseases Hospital, China | 2025-02-01 |
| A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem Cell Transplant Patients (NCT06792630) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-31 |
| Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia (NCT06769568) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-31 |
| Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML (NCT06757855) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-26 |
| HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML (NCT06744556) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-21 |
| Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT (NCT06783790) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-20 |
| A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia (NCT06770504) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-16 |
| A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia (NCT06776510) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-15 |
| Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (NCT06744504) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-10 |
| Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol (NCT06764238) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-03 |
| Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia (NCT06643195) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-01 |
| BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy (NCT06769555) | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-01 |
| Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML (NCT06758726) | Institute of Hematology & Blood Diseases Hospital, China | 2024-12-31 |
| BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma (NCT06745687) | Institute of Hematology & Blood Diseases Hospital, China | 2024-12-30 |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas (NCT06716658) | Institute of Hematology & Blood Diseases Hospital, China | 2024-12-25 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. (NCT06733610) | Institute of Hematology & Blood Diseases Hospital, China | 2024-12-05 |
| Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia (NCT06931912) | Institute of Hematology & Blood Diseases Hospital, China | 2024-12-01 |
| Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) (NCT06712173) | Institute of Hematology & Blood Diseases Hospital, China | 2024-12-01 |
| CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases (NCT06680388) | Institute of Hematology & Blood Diseases Hospital, China | 2024-11-15 |
| EPOCH-Economics and Patient Outcomes in China in Haemophilia (NCT07454239) | Institute of Hematology & Blood Diseases Hospital, China | 2024-11-14 |
| Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation (NCT06658938) | Institute of Hematology & Blood Diseases Hospital, China | 2024-11-01 |
| Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia (NCT06695741) | Institute of Hematology & Blood Diseases Hospital, China | 2024-11-01 |
| Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL (NCT06658925) | Institute of Hematology & Blood Diseases Hospital, China | 2024-11-01 |
| Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia (NCT06613880) | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-24 |
| The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation (NCT06561880) | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-08 |
| Tislelizumab with Azacitidine in the Treatment of R/R AML (NCT06586099) | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-05 |
| Twice-per-weekSelinexor, 2 Days Melphalan (NCT06613035) | Institute of Hematology & Blood Diseases Hospital, China | 2024-09-30 |
| Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML (NCT06635681) | Institute of Hematology & Blood Diseases Hospital, China | 2024-09-29 |
| Intermediate-dose HAD Regimen for CEBPA Double-mutated AML (NCT06529250) | Institute of Hematology & Blood Diseases Hospital, China | 2024-08-13 |
| Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia (NCT06530576) | Institute of Hematology & Blood Diseases Hospital, China | 2024-08-10 |
| PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas (NCT06530550) | Institute of Hematology & Blood Diseases Hospital, China | 2024-08-10 |
| Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia (NCT06386302) | Institute of Hematology & Blood Diseases Hospital, China | 2024-08-05 |
| Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. (NCT06608732) | Institute of Hematology & Blood Diseases Hospital, China | 2024-08-01 |
| Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) (NCT06838962) | Institute of Hematology & Blood Diseases Hospital, China | 2024-08-01 |
| Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis (NCT06525519) | Institute of Hematology & Blood Diseases Hospital, China | 2024-07-31 |
| Prospective Observational Clinical Study on Changes in Cognitive Levels in Elderly Patients Before and After Hematopoietic Stem Cell Transplantation (NCT06484049) | Institute of Hematology & Blood Diseases Hospital, China | 2024-07-30 |
| Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma (NCT06504199) | Institute of Hematology & Blood Diseases Hospital, China | 2024-07-18 |
| Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas (NCT06513234) | Institute of Hematology & Blood Diseases Hospital, China | 2024-07-11 |
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia (NCT06427330) | Institute of Hematology & Blood Diseases Hospital, China | 2024-07-02 |
| Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI (NCT06490562) | Institute of Hematology & Blood Diseases Hospital, China | 2024-07-01 |
| Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD (NCT06473909) | Institute of Hematology & Blood Diseases Hospital, China | 2024-07-01 |
| the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia (NCT06461091) | Institute of Hematology & Blood Diseases Hospital, China | 2024-07-01 |